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Accepted 15 March 2008RNA interference (RNAi) is a promising antiviral methodology. We recently demonstrated that retroviral
vectors expressing short-hairpin RNAs (shRNA-mirs) in the context of a modiﬁed endogenous micro-RNA
(miRNA) can be effective in reducing replication of other retroviruses in chicken cells. In this study, similar
RNAi vectors are shown to inhibit replication of the avian herpesvirus, Marek's disease virus (MDV, also
known as gallid herpesvirus type 2), and its close relative, herpesvirus of turkeys (HVT). Cells expressing
shRNA-mirs targeting the MDV or HVT gB glycoprotein gene or the ICP4 transcriptional regulatory gene show
signiﬁcant inhibition of viral replication. Not only are viral titers reduced, but observed plaque sizes are
signiﬁcantly smaller when the virus is grown on cells in which RNAi is effective. We also describe a modiﬁed
retroviral delivery vector that expresses a shRNA-mir containing up to three RNAi target sequences and
employ this vector with multiple targets within the MDV gB gene or within both the gB and ICP4 genes. The
use of targets within multiple genes potentially can provide a larger antiviral effect and/or make it more
difﬁcult for viral escape mutations to evolve.
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RNA interference (RNAi) is a promising antiviral strategy (Hu et al.,
2002; Berkhout and Haasnoot, 2006; Cullen, 2006; Leonard and
Schaffer, 2006). RNAi is mediated by short RNA oligonucleotides that
bind to, suppress translation of, and sometimes induce cleavage of
complementary mRNAs. RNAi generally arises from two types of
intermediary molecules: small interfering RNAs (siRNAs) and micro-
RNAs (miRNAs: Tang, 2005; Valencia-Sanchez et al., 2006). siRNAs are
~22 base-pair (bp) double-stranded oligonucleotides that can be
chemically synthesized and introduced directly into cells or processed
from short-hairpin RNAs (shRNAs) that are transcribed from trans-
fected vectors (Nakahara and Carthew, 2004). More recently,
endogenous miRNA genes transcribed as larger “pri-miRNA” pre-
cursors have been found to more effectively generate an RNAi effect
(Boden et al., 2004; Silva et al., 2005; Dickins et al., 2005). In this case
(termed shRNA-mirs; Zeng et al., 2002), the stem region of a miRNA
gene is replaced with the target sequence and its guide RNA
complement. We previously described retroviral vectors based on
the replication-competent avian leukosis virus constructs developed
by Hughes and colleagues (Hughes et al., 1987; Federspiel and Hughes,ical Sci. Bldg., Michigan State
17 353 8957.
ew@msu.edu (W.S. Payne),
s.usda.gov (H. Zhang),
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l rights reserved.1997) that express shRNA-mirs either as spliced sub-genomic RNAs
transcribed from the retroviral long terminal repeat (LTR) promoter or
as short RNAs transcribed from internal promoters (Chen et al., 2007).
We further demonstrated the efﬁcacy of such vectors in inhibiting
replication of subgroup B avian leukosis virus in cultured chicken cells.
Retroviral vectors have been used in large scale RNAi mutagenesis of
endogenous genes (reviewed in Chang et al., 2006; Root et al., 2006)
but only rarely to inhibit the growth of other viruses.
The replication of several herpesviruses has been inhibited by
RNAi, mostly using exogenously administered, synthetic siRNAs. These
include murine herpesvirus 68 (Jia and Sun, 2003), Epstein–Barr virus
(Chang et al., 2004), Kaposi's sarcoma-associated herpesvirus (e.g.,
Godfrey et al., 2005), HSV-1 (Bhuyan et al., 2004), herpesvirus-6B
(Yoon et al., 2004), human cytomegalovirus (Wiebusch et al., 2004), a
duck herpesvirus (Mallanna et al., 2006) and HSV-2 (Palliser et al.,
2006). Palliser et al. (2006) demonstrated that siRNAs (including those
targeting gB glycoprotein mRNA) could block lethal HSV-2 challenges
in mice when administered exogenously either before or after the
virus. However, retroviral delivery offers the prospect of more stable
and cost-effective antiviral RNAi in live animals than do synthetic
siRNAs. The goal of this study was to inhibit MDV replication using
shRNA-mirs delivered by retroviral infection.
MDV (also known as gallid herpesvirus type 2, GaHV-2) is a
herpesvirus that causes Marek's disease, a lymphoproliferative
disorder in which aggressive T-cell lymphomas result from infection
of susceptible chickens (Calnek and Witter, 1997). MDV is a major
chronic infectious disease concern for the world's poultry industry
Table 2
Reduction in MDV and HVT plaque sizes due to RNAi against gB
Retroviral vector and RNAi target
RCASBP(A)miRNA Md11 MDV gB RCASBP(A)miRNA-sphngo FC126 HVT gB
Construct Mean⁎ SD⁎ Construct Mean⁎ SD⁎
Mock 135AB 47 Mock 129A 50
Scrambled 140A 48 Scrambled 83AB 34
2541 153A 69 gB2 27C 13
1874 28C 11 gBcshl2 41BC 29
1518 72BC 31
596 57C 42
⁎All units are in µm2×103. Mean values within a column not sharing a common letter
superscript are statistically different at Pb0.005. SD=standard deviation.
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(Osterrieder et al., 2006). Since 1970, Marek's disease has been
controlled primarily by vaccination (Calnek and Witter, 1997) with
HVT or with one or more attenuated MDV isolates. However, since
vaccination blocks tumor formation rather than viral replication, MDV
continues to multiply and evolve in vaccinated ﬂocks. In addition to
escaping vaccine control, MDV also appears to be evolving greater
virulence and the ability to generate more acute disease symptoms
(Witter, 1997; Nair, 2005; Osterrieder et al., 2006). MDV genomes
range from about 174 to 180 kb in size, and each encodes
approximately 100 proteins. Genetic analysis has demonstrated that
the gB, gE, gI, gM, UL49.5 and UL49–VP22 genes are required for MDV
growth (Schumacher et al., 2000, 2001; Tischer et al., 2002; Dorange
et al., 2002). Several other MDV genes are necessary either for full
infectivity and/or for pathogenesis in vivo (reviewed in Osterrieder
et al., 2006). We initially chose to test RNAi using the gB gene (Yoshida
et al., 1994) as our target, as it encodes a major surface glycoprotein
that is easy to detect with a monoclonal antibody. The gB glycoprotein
also has a major role in protective immunity (Ross et al., 1996).
Subsequently, we also used the key transcriptional regulatory gene,
ICP4, as a target. The HSV1 ICP4 gene has been demonstrated to be
essential for viral replication (Preston, 1979; Dixon and Schaffer, 1980;
DeLuca et al., 1985; Compel and DeLuca, 2003). Moreover, Trang et al.
(2000, 2001) showed that expression of RNaseP-derived ribozymes
against HSV1 ICP4 mRNA reduced viral growth. Jia and Sun (2003)
demonstrated RNAi against murine herpesvirus 68 using the Rta gene
as a target, and Rta functions as an early regulator of viral transcription
in gamma-herpesviruses in a somewhat analogous fashion to the role
of ICP4 in MDV (Pavlova et al., 2003; Feederle et al., 2000). These
experiments suggest that reductions in ICP4mRNA levels can generate
an antiviral effect. In addition to its role in lytic infection, ICP4 is one of
a few genes expressed in cells that harbor latent MDV genomes.
Several labs have demonstrated that latently infected cells naturally
express a family of antisense transcripts to ICP4 (LATs: Cantello et al.,
1994, 1997; Li et al., 1994, 1998; McKie et al., 1995; Ohashi et al., 1994).
The function of LATs and the mechanism(s) by which they might
modulate ICP4 activity remain unclear, but Xie et al. (1996) showed
that antisense oligonucleotides or expression of antisense RNA to ICP4
inhibited the proliferation of MDV-transformed MSB1 cells. In
addition, Burnside et al. (2006) recently identiﬁed two clusters of
miRNAs in theMDV genome, one of which was at the 5′ end of the LAT
region, just downstream of ICP4.
Results
Inhibition of HVT by retroviral delivery of shRNA-mirs targeted against
the gB gene
Wepreviously described RCASBP(A)miRNA (Supplemental Fig.1), a
retroviral vector containing 417 bp of the chicken miR-30a geneTable 1
Effect of retroviral RNAi vector treatment using gB gene targets on FC126 HVT infection
FC126 HVT gB target shRNA-mir30aa shRNA-mir30a-sphngoa
Meanb Std. error Meanb Std. error
FgB1 1.1 0.13 NDc NDc
FgB2 0.3d 0.04 0.32d 0.03
FgB3 1.1 0.13 NDc NDc
FgBcshl2 0.4d 0.03 0.45d 0.02
FgBcshl3 0.5d 0.02 NDc NDc
Scrambled 1.1 0.03 0.93 0.05
a Type of pENTR3C entry vector employed to insert target.
b Average titer of each retroviral treatment divided by the average titer after mock
infection.
c ND, not done.
d Statistical difference of Pb0.01 from mock treatment within a column.modiﬁed to contain MluI and NcoI restriction sites for insertion of
99 bp synthetic duplex target sequences using a modiﬁed pENTR3C
entry plasmid and Gateway® (Invitrogen Corp.) recombination
technology (Chen et al., 2007). Subsequently, an alternative miR-
30a-based entry vector that accepts shorter synthetic duplexes (78 bp)
between SphI and NgoMIV sites has been created (pENTR3C-miR30a-
sphngo, Supplemental Figs. 1 and 2). In both cases, the modiﬁed miR-
30a transcript is expressed from the retroviral LTR via a sub-genomic
spliced mRNA. The viral vectors were used to transfect DF-1 avian
ﬁbroblasts (Schaefer-Klein et al., 1998) in which they are replication-
competent. After the vectors spread throughout the culture, cells were
challenged with HVT followed by a plaque assay (Materials and
methods). Five different target sequences (Supplemental Table 1)
were chosen within the HVT gB sequence using methods described
previously (Chen et al., 2007). Three out of the ﬁve shRNA-mirs (FgB2,
FgBcshl2 and FgBcshl3) signiﬁcantly reduced HVT plaque numbers in
comparison either to mock-transfected DF-1 cells or to DF-1 cells
treated with RCASBP(A)miRNA containing a scrambled target
sequence (Table 1). The most effective target (FgB2) reduced plaque
numbers to about 30% of that of the controls. As previously described
for other targets (Chen et al., 2007), no reduction in HVT titer was
observed when the same gB sequences were inserted into a miR-30a
gene downstream of a chicken U6 polymerase III promoter in the
RCANBP(A) delivery vector (data not shown). Two of the effective HVT
gB targets, FgB2 and FgB-cshl2, were subsequently inserted as shorter
duplexes into the pENTR3C-miR30a-sphngo entry vector followed byFig. 1. RCASBP(A)shRNA-mir directed against Md11 MDV gB reduces plaque numbers in
both CEF (blue bars) and SOgE cells (purple bars). Four different shRNA-mirs against
MDV gB (Supplemental Table 1), along with a scrambled control sequence, were
delivered to CEF and SOgE cells via the RCASBP(A)miRNA vector (Supplemental Fig. 1).
Targets are identiﬁed by the number of their ﬁrst nucleotide within the Md11 gB coding
sequence (Supplemental Table 1). Cells were infectedwith 100 to 400 pfu of Md11MDV.
Plaques were counted at 5 dpi and normalized to the mock-infected control as 1.0.
Histogram bars labeled with different letters are signiﬁcantly different within either the
CEF or SOgE cell groups, respectively (Pb0.05).
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The use of shorter synthetic target inserts should provide higher
sequence reliability at lower cost.
Since gB functions as a membrane fusion protein, any reduction in
gB expression could impact viral spread between cells and thus
produce a distinct plaque phenotype. Table 2 shows that the mean
plaque sizes for the FgB2 and FgB-cshl2 groups were signiﬁcantly
smaller than those observed on mock-treated cells (Pb0.005). Indirect
immunoﬂuorescence (IIF) staining using a monoclonal antibody
speciﬁc for the HVT gB protein conﬁrmed the small plaque phenotype
and also demonstrated a reduction in gB ﬂuorescence within the
stained plaques treated with effective RNAi vectors (data not shown).
Antiviral RNAi against MDV (GaHV-2) using gB gene targets
We next investigated whether RNAi against the viral gB gene could
inhibit pathogenic serotype 1 strains of MDV (GaHV-2) in cell culture.
MDV and HVT gB proteins are only 81% identical and their respective
genes are about 75% identical (Tulman et al., 2000; Afonso et al., 2001;
Kingham et al., 2001) in nucleotide sequence, so four speciﬁc RNAi
target sites were designed for the MDV gB gene (strain Md11; Niikura
et al., 2006). These assays were performed in chicken embryo
ﬁbroblasts (CEF) since they are more permissive to serotype 1 MDV
infection. When delivered using RCASBP(A)miRNA, three of the four
targets gave rise to a signiﬁcant (Pb0.05) reduction in plaque number,
with the most effective target (1874) reducing titers to about 16% of
the control (Fig.1). Again, MDV plaque sizes were reduced and showed
reduced gB expression by IIF (Fig. 2 and Table 2) in the three cultures
treated with effective RNAi target sequences (1874, 1518, and 596,
where the number indicates the ﬁrst nucleotide of the target site in
the gB coding sequence, Supplemental Table 1).Fig. 2. a. Morphology of Md11MDV plaques on CEF at 5 dpi. Four different MDV gB target sequ
to CEF via the RCASBP(A)miRNA vector. CEF cells were infected with 100 to 400 pfu of Md11M
size. A magniﬁcation scale is inserted in the Mock panel. b. IIF analysis of representative M
sequences as described in Fig. 2.a. At 5 dpi, cells were ﬁxed with acetone: alcohol (60:40
immunoglobulin G conjugated to FITC (Molecular Probes). Three gB-speciﬁc RNAi treat
Magniﬁcation, ×250.Recently, a permanent cell line, SOgE, that constitutively expresses
the MDV gE glycoprotein, has been established for propagation of
virulent strains of MDV (Schumacher et al., 2002). We delivered
RCASBP(A)miRNA vectors into SOgE cells via nucleofection (Materials
and methods) and monitored their spread through the culture by
ﬂuorescence microscopy and ﬂow cytometry. In a RCASBP(A)-GFP
transfected culture, more than 90% of the cells were positive for GFP
expression after four passages (data not shown). We then employed
these transfected SOgE cells in plaque assays of Md11 MDV. The three
constructs that reduced plaque numbers in CEF also signiﬁcantly
inhibited plaque formation in SOgE cells (Pb0.05), although the most
effective target sequence (1874) showed less inhibition in SOgE cells
than in CEF (Fig. 1). As expected, the other target (2514) and a control
scrambled sequence target did not signiﬁcantly reduce plaque
numbers. The reduced inhibition in SOgE cells may relate to the use
of transfection to deliver the RNAi vector to these cells or to the fact
that, in our hands, Md11 generates smaller plaques on these cells even
in the absence of RNAi.
Antiviral RNAi against MDV using a three target vector with ICP4 and/or
gB target sequences
Wemodiﬁed our vector system such that multiple shRNA-mirs can
be transcribed within a single pri-miRNA-like precursor. At least two
putative endogenous chicken pri-miRNA-encoding genes generate
transcripts predicted to contain 6miRNAhairpins, one on chromosome
1 (employed by Das et al., 2006) and another on chromosome 4. We
chose to use the second locus for ease of construction. The sequence in
question was modiﬁed to generate a cassette that contains three
miRNA sites (miR-20b, miR-92-2 and miR-19b), each of which is
ﬂanked by a pair of unique restriction sites allowing for the insertion ofences (Supplemental Table 1), along with a scrambled control sequence, were delivered
DV. Two gB-speciﬁc RNAi treatments (1874 and 596) of CEF cells show a reduced plaque
d11 plaques in CEF. CEF were infected with RCASBP(A)miRNA vectors with gB target
) and incubated with MDV gB MAb IAN86. The secondary antibody was anti-mouse
ments (1874, 596 and 1518) demonstrate reduced gB expression and plaque size.
Fig. 3. RCASBP(A)3mirs directed against subgroup MDV gB and/or ICP4 reduces titers in
CEF. miRNAs against MDV gB and/or ICP4 (Supplemental Table 1), along with scrambled
control sequences, were delivered to CEF via the RCASBP(A)3mirs vector (Supplemental
Fig. 1). Targets are identiﬁed by the number of their ﬁrst nucleotide within the MDV gB
or ICP4 coding sequence, respectively (Supplemental Table 1). In each case, the ﬁrst
sequence in a series is in the miR-20b site, the second in the miR-19b site and the third
in the miR-92-2 site. Scr1, 2 and 3 indicate different scrambled control sequences with
similar base compositions to the targets. gB targets are 1874, 596 and 1518, whereas
ICP4 targets are 4902 or 6170. Cultures were infected with 100 pfu of Md5 MDV.
Plaques were counted at 5 dpi and normalized to the mock-infected control as 1.0.
Histogram bars labeled with different letters are signiﬁcantly different (Pb0.01).
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(RCASBP(A)3mirs, Supplemental Fig. 1) using single MDV gB target
sequences demonstrated that each of the three sites individually can
generate an effective RNAi response (data not shown). RCASBP(A)
3mirs was then used to deliver one, two or three of the gB gene targets
previously shown to be effective. In this case, including two additional
gB targets (596 and 1518) did not significantly add to the antiviral effect
observed using the best single gB target (1874) alone (Fig. 3).
The multi-target RNAi vector then was used to explore the
effectiveness of the MDV ICP4 gene as a target. We ﬁrst tested
individual target sequences within ICP4. Two of four ICP4 targets
chosenwere able to signiﬁcantly reduce plaque numbers to about 30%
of the control (Fig. 3, only the two effective targets are shown). The
effective gB and ICP4 targets were then combined within single multi-
target vectors. Fig. 3 shows that the addition of the best ICP4 target
sequence (6170) to one or two gB targets enhances the antiviral effect
observed, with the best construct (1874-gB, 6170-ICP4, 1518-gB)
reducing the MDV titer to nearly 5% of the mock-infected control
(Fig. 3). Given that RNAi reduced MDV viral replication as a whole, we
expected at least a concomitant reduction in viral target mRNA levels.
Indeed, reverse transcriptase PCR (RT-PCR) measurements demon-
strated that reduction of gB mRNA levels correlated well with the
reduction in MDV plaque number (Fig. 4). For one of the four
experiments whose results are summarized in Fig. 3, we also
measured replication of MDV viral DNA via quantitative PCRFig. 4. RT-PCR of gBmRNA expression from CEF expressing RCASBP(A)3mirs. CEF were infec
described in Materials and methods. GAPDH mRNA was assayed as a loading control. Mock
transcriptase. In each case, the ﬁrst sequence in a series is in the miR-20b site, the second
scrambled control sequences with similar base compositions to the targets. gB targets are 1
number of their ﬁrst nucleotide within the MDV gB or ICP4 coding sequence, respectively (comparing the level of MDV gB gene DNA to that of the host cell
GAPDH gene (Supplemental Fig. 4). These results correlated well
(correlation coefﬁcient=0.70, similar to, or higher than, those
observed by Bumstead et al., 1997 and Baigent et al., 2005) with the
titers shown in Fig. 3, although the inhibition was somewhat less
pronounced, at least for vectors containing the 1874-gB target. PCR-
based methods measure all forms of the viral genome (Baigent et al.,
2005), including, presumably, genomes that fail to be infectious due to
a deﬁcit in, for example, gB protein. Thus, we view inhibition of viral
titers as the most relevant quantitative measure of the RNAi effect.
Discussion
We have demonstrated the use of retroviral vector-based RNAi
against MDV, a major pathogenic threat in chickens. Three different
shRNA-mir gene constructs, delivered via a replication-competent
retroviral vector, successfully reduced viral replication using targets in
two very different viral genes, gB and ICP4. The gB glycoprotein gene
is known to be essential for MDV replication (Schumacher et al., 2000)
and is likely involved in viral spread from cell to cell, whereas the ICP4
gene, known to be essential in other herpesviruses, acts as a
transcription factor. The ICP4 effect occurs in spite of the fact that
this immediate early protein is transportedwithin infectious virions in
HSV1 (Yao and Courtney, 1989), which could provide a source of the
protein resistant to any RNAi effect. However, the complementation
studies of Dargan and Subak-Sharpe (1997) suggest the need for
additional de novo ICP4 synthesis during the viral life cycle after the
initial infection.
The results reported here conﬁrm our earlier observation (Chen
et al., 2007) and those of others (Boden et al., 2004; Silva et al., 2005;
Dickins et al., 2005) that embedding the RNAi target within a pri-
miRNA gene transcribed by an RNA polymerase II promoter provides
an effective delivery method. Since many pri-miRNA genes are
polycistronic (Lagos-Quintana et al., 2001), the possibility exists to
express multiple RNAi target sequences within a single transcript (Yu
et al., 2003; Chung et al., 2006; Das et al., 2006). Indeed, the
endogenous chicken chromosome 4 miRNA cluster that we have
modiﬁed to deliver three targets originally contained six potential
miRNAs, although it has not been proven that all six are expressed. Our
results demonstrate that all three target sites in our vector can be
functional. However, combining either three different gB gene targets
or one ICP4 target and two gB targets, each of which was known to
inhibit on its own, did not always increase the antiviral effect in an
additive fashion. For example, although the 596-gB and 1518-gB
targets were effective on their own, they did not signiﬁcantly enhance
the antiviral effect of 1874-gB when added to the multi-target vector
(Fig. 3). On the other hand, adding 1518-gB to 1874-gB plus 6170-ICP4
produced a greater reduction inMDV titer than did 1874-gB plus 6170-
ICP4 alone [a direct comparison of the 1874–6170-scrambled control
result with that of 1874–6170–1518 gave a signiﬁcant difference
(Pb0.05 using Student's t test), but the difference did not reachted with 100 pfu of Md5 MDV, and RNA was isolated at 5 dpi. RT-PCR was performed as
no RT: RT-PCR was performed using RNA from Mock treatment without added reverse
in the miR-19b site and the third in the miR-92-2 site. Scr1, 2 and 3 indicate different
874, 596 and 1518, whereas ICP4 targets are 4902 or 6170. Targets are identiﬁed by the
Supplemental Table 1).
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Duncan's test]. Clearly, many factors modulate the effectiveness of any
given viral target gene and any speciﬁc target sequence within that
gene. We are currently exploring the use of additional targets and
additional combinations of targets within our multi-target vector to
address some of these issues. Regardless of whether multiple targets
provide a substantially greater antiviral effect, this approach may also
have value in making it more difﬁcult for the virus to evade the RNAi
effect through a mutation in the target sequence(s). RNAi escape
mutants have been documented for HIV, poliovirus, and hepatitis B
and C viruses (reviewed in Leonard and Schaffer, 2006). However viral
escape mutations appear to be less frequent in DNA viruses such as
MDV, and Palliser et al. (2006) found no mutations in the UL29 target
region in HSV-2 in the course of blocking lethal effects of HSV-2 using
RNAi in vivo.
Retroviral-delivered RNAi reduced both the number and size of
MDV plaques. These two properties are likely due to the same central
effect, since reducing the size of plaques to the point that they are no
longer visible will inevitably reduce the titer. In any case, both
observations suggest a potentially signiﬁcant antiviral effect may be
obtained via in vivo delivery of RNAi against MDV. We are presently
engaged in experiments to test this possibility. Although the reduc-
tions in titer that we have observed are generally modest, it should be
noted that genetic resistance/susceptibility to MDV is a highly
multigenic trait (Vallejo et al., 1998; Yonash et al., 1999) involving
minor contributions from many polymorphic alleles to achieve, in
some cases, high levels of total resistance. Thus, even a partial block in
viral replication could signiﬁcantly lower the frequency and/or the
severity of Marek's disease in vivo. RNAi inhibition of viral replication
should also reduce the rate at which MDV evolves in the ﬁeld to evade
vaccination or to increase virulence (Osterrieder et al., 2006). While
replication-competent vectors are unlikely to be of practical value in
the ﬁeld, they provide a useful model system in which to test targets
thatmight later be incorporated into replication-defective retroviruses
or other viral vectors. Anti-viral shRNA-mirs could be effectively
delivered to chickens via transgenics (Salter et al., 1987; Mozdziak et
al., 2003; McGrew et al., 2004) or as a part of a vaccine potentially to
create viral-resistant chicken populations (Hu et al., 2002). Additional
research will be required to demonstrate an antiviral effect in vivo and
to overcome the barriers to implementing such a strategy.
Materials and methods
Vector constructions
The construction of the RCASBP(A)miRNA vector and the corre-
sponding pENTR3C-miR30a entry vector has been described pre-
viously (Chen et al., 2007). The pENTR3C-miR30a-sphngo entry vector
(Supplementary Fig. 2) was made in an analogous fashion using the
overlapping PCR technique of Ho et al. (1989) to insert SphI and
NgoMIV restriction sites into the mir-30a target region. Primers used
in the construction and the resultant insert sequence are shown in
Supplemental Fig. 2. The PCR product was cleaved with BamH1 and
NotI and inserted into the pENTR3C vector (Invitrogen Corp.) as
described previously (Chen et al., 2007).
The pENTR3C-3mir entry vector was constructed using similar
methodology. We chose to use the chicken miRNA cluster at
3,968,600–3,970,600 on chromosome 4 of the v2.1 build of the chicken
genome sequence (http://genome.ucsc.edu/cgi-bin/hgGateway). The
genome sequence in this region includes a gap that can be ﬁlled using
two overlapping chicken EST sequences (BU384584 and BU337076)
that, together, likely correspond to most, but not all, of the pri-miRNA
transcribed from this cluster. BU384584 includes miRNAs from the
miR-18b, miR-20b, miR-19b and miR-92-2 families and most of a
member of themiR-363 family. In addition, there is (at least) a member
of themiR-106a family just upstreamof the BU384584 cluster.We choseto use the miR-20b, miR-19b and miR-92-2 segment of this cluster,
deleting themiR-363 familymember, but retainingpart of thepresumed
3′ end of the pri-miRNA in our construct. The sequence of the resulting
insert and the PCR primers used to construct it are shown in
Supplementary Fig. 3. Two PCR duplexes were generated that were
cleavedwith, respectively, HindIII and AvrII and AvrII and NotI, and then
were cloned into HindIII–NotI-cut pENTR3C in a three-way ligation.
pENTR3C-3mir contains the complete miR-19b family member gene
which can be removed and replaced using BspEI/EcoRI digestion and
two small ﬁller sequences at the sites of the miR-20b and miR-92-2
family members ﬂanked by unique AvrII and BglII and BamHI and AgeI
sites, respectively (Supplementary Figs. 1 and 3).
RNAi target sequences were chosen by computer analysis as
described previously (Chen et al., 2007). Target sequences were
embedded within oligonucleotides designed to mimic, as nearly as
possible, the endogenous ﬂanking and loop miRNA sequence(s) that
were obtained in polyacrylamide gel-puriﬁed form from commercial
sources (Invitrogen Corp. or Integrated DNA Technologies). Duplexes
were annealed and ligated into appropriately-digested entry vectors.
Oligonucleotide sequences used are listed in Supplementary Table 1.
All entry vector inserts were conﬁrmed by DNA sequence analysis,
after which the relevant insert was transferred into the RCASBP(A)
destination vector using a Gateway® LR reaction according to the
manufacturer's recommendations (Invitrogen Corp.). Retroviral vector
constructs were veriﬁed by restriction digestion using appropriate
unique sites within insert cassettes. For the RCASBP(A)shRNA-mir
1874 construct, versionswere tested that either contained or lacked an
internal U6 promoter in addition to the viral LTR, with only the results
of the former shown in Figs. 1 and 2. No signiﬁcant difference in effect
was observed between the two constructs. All other constructs lack
the U6 internal promoter.
Cells and viruses
DF-1 cells were maintained in Leibowitz's L-15 and McCoy 5A
media (1:1) supplemented with 10% fetal bovine serum (FBS, Atlanta
Biologicals), 50 µg/ml of gentamicin (Invitrogen), and 0.25 µg/ml of
fungizone at 39 °C. CEF cells were maintained in the same media
supplemented with 4% calf serum (Invitrogen Corp.). SOgE cells were
maintained in Dulbecco's modiﬁed Eagle's mediumwith 7.5% FBSwith
selection in 1 mg/ml of G418 (Invitrogen Corp.) once every ﬁve
passages (Schumacher et al., 2002). The serum content for MDV- or
HVT-infected cells was reduced to 1% when cells reached conﬂuence.
Md11 (80 passages in CEF) and Md5 (42 passages in CEF) MDV strains
and the FC126 strain of HVT were obtained from Richard Witter and
Mohammad Heidari, USDA-ARS, Avian Disease and Oncology Lab
(ADOL). The Md11 MDV used to infect SOgE cells was passed in these
cells four times prior to use.
Delivery of RCAS and RCAN vectors into cell culture
Propagation of RCASBP(A) vectors in DF-1 cells was initiated by
transfection of plasmid DNA containing the retroviral provirus using
SuperFect Transfection Reagent (Qiagen, Inc.) according to the
manufacturer's protocol. Viral spread was monitored by assaying
culture supernatants for ALV capsid protein by ELISA (Smith et al.,
1979). RCASBP(A) stocks were generated from cell supernatants by
centrifugation at 1500 ×g for 10 min at 4 °C and stored in aliquots at
−80 °C. RCASBP(A) vectors were delivered into CEF cells by infection of
virus grown on DF-1 cells. Brieﬂy, 106 CEF were seeded on 10 cm
dishes and allowed to attach overnight. Viral stocks were added to DF-
1 media at a MOI of 1.0. CEF were then incubated in virus-containing
media with 4 µg/ml polybrene for 24 h before being replaced with
fresh medium. Sample supernatants were collected after one passage
and infectionwasmonitored by ELISA as described above. Propagation
of RCASBP(A) vectors in SOgE cells was initiated by transfection of
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supplied Basic Fibroblast Kit (Amaxa Biosystems). RCASBP(A) spread
was monitored using a Becton-Dickinson FACSCalibur (BD Bios-
ciences) machine using a subgroup(A) ALV-speciﬁc antibody (RAV-1,
a gift from Lucy Lee, ADOL). GFP expression from the RCASBP(A)-GFP
vector was also detected by ﬂuorescence microscopy as described
previously (Chen et al., 2007).
Plaque assays
DF-1 cells expressing shRNA-mir constructs were infected by
FC126 HVT as follows: 5.0×105 cells were seeded on 6-well plates and
allowed to attach overnight. Four hundred plaque forming units (pfu)
were added in DF-1 media followed by incubation for up to 4 dpi.
Plaques were observed and counted under a LEICA DM IRB/E inverted
microscope (Leica Wetzlar), and images were captured by a DEL-
750CE digital system. Plaque assays were repeated four times (shRNA-
mir30a) or three times (shRNA-mir30a-sphngo), each time in
duplicate (Table 1). CEF and SOgE cells expressing shRNA-mir
constructs were infected with 100 to 400 pfu of Md11 or Md5 strains
of MDV in a similar fashion, except that plaques were counted at 5 dpi.
Plaque assays employing RCASBP(A)miRNA (Fig. 1) were repeated
twice (CEF cells) or three times (SOgE cells). Plaque assays employing
RCASBP(A)3mirs (Fig. 3) were repeated four times.
Immunoﬂuorescence assay
DF-1 cell monolayers (4 dpi with 400 pfu of FC126 strain HVT)
were ﬁxed with ice-cold 40% ethanol and 60% acetone and incubated
with the primary L78 antibody (gift from Lucy Lee, ADOL) for 30 min
as described (Lee et al., 1983). Cells were washed three times with
phosphate-buffered saline (PBS) and incubated with the secondary
antibody, FITC-labeled goat anti-mouse IgG (MP Biomedicals) for
30 min. After three washes with PBS, cells were examined under the
ﬂuorescent microscope. CEF cells were infectedwithMd11 strainMDV
at 100 or 150 pfu and incubated up to 5 days. Plaques were stained in a
similar manner except that the primary antibodywas IAN86 (gift from
Lucy Lee, ADOL).
Plaque size measurement
DF-1 cells previously treated with RCASBP(A)miRNA-sphngo were
infected by 400 pfu of FC126 HVT. DF-1 cells monolayers (4 dpi) in 6
well plates were then ﬁxed with ice-cold 40% ethanol and 60%
acetone. Plaque images were captured using a DEL-750CE digital
system. CEF previously treated with RCASBP(A)miRNA were infected
by 100 to 400 pfu of Md11 strain MDV in a similar fashion, except that
plaques images were captured at 5 dpi. For size comparisons, 8 to 15
randomly chosen plaques (a sufﬁcient number to achieve statistical
signiﬁcance according to pilot experiments) for each treatment were
analyzed using ImageJ (freeware from the National Institutes of
Health; http://rsb.info.nih.gov/ij/index.html). To ensure random sam-
pling, all plaques in a 10 mm diameter circle in the center of the plate
were measured; if fewer than 8 plaques were found in this area, the
diameter of the circle was increased to 15 mm. Plaque images were
ﬁrst processed using ImageJ to increase the picture quality. Plaque size
measurement was performed according to the Measuring and
Counting Objects Instruction (http://rsb.info.nih.gov/ij/docs/index.
html). The unit and scale were set at 1.058 pixels/µm based on a
known micrometer ruler. Both HVT and MDV plaques were measured
from 3 independent experiments.
Flow cytometry
For ﬂow cytometric analysis of RCASBP(A) propagation in SOgE
cells, cells were incubated with the primary antibody, RAV-1, for30 min at 4 °C. Cells were washed three times with DMEM containing
1% FBS followed by centrifugation (1000 ×g, 5 min). Cells were then
incubated with the secondary antibody, FITC-labeled goat anti-mouse
IgG (MP Biomedicals), for 30min at 4 °C. After threewashes, cells were
analyzed using a Becton-Dickinson FACScaliber ﬂow cytometer and
CellQuest Pro software (BD Bioscience).
Reverse transcriptase PCR (RT-PCR)
CEF expressing various RCASBP(A)-3mirs were challenged with
100 pfu of Md5 strain MDV. RNAwas collected at 5 dpi and treated with
DNase I using the RNeasy kit according to manufacturer's instructions
(Qiagen, Inc.). One microgram of RNA was reverse transcribed with
Moloney murine leukemia virus (M-MLV) reverse transcriptase (Invi-
trogen Corp.) in a 20-µl reaction volume. Ampliﬁcations of gB and
chicken GAPDH sequences were carried out in separate reactions using
the following primers:GAPDH forward, TGACAAGTCCCTGAAAATTGTCA;
GAPDH reverse, CAAGGGTGCCAGGCAGTT; gB forward, CCAGTGGGTT-
CAACCGTGA; and gB reverse, CGGTGGCTTTTCTAGGTTCG (gifts from
Robert Silva, ADOL). PCR was done in 50 µl containing 25 µl 2× PCR
mastermix (PromegaCorp.), 2 µL cDNA, andprimers at 2.5 pmol each for
2 min at 95 °C followed by 20 cycles (24 cycles for gB) of 1 min at 95 °C,
30 s at 52.5 °C (57 °C for gB) and 30 s at 72 °C. cDNA prepared frommock
infection minus reverse transcriptase (no −RT Mock) and from CEF
without Md5 (CEF) were used as negative controls.
Quantitative real time PCR (qPCR) assay for viral genomes
CEF expressing various RNAi constructs were challenged with
100 pfu of Md5 strain MDV. DNA was collected at 5 dpi using the
DNeasy Blood & Tissue kit and treated with RNase I according to
manufacturer's instructions (Qiagen, Inc.). DNA was diluted to a
concentration of 20ng/µl for use in the qPCRassay. pCRBlunt (Invitrogen
Corp.) plasmids (gifts from Dr. Robert Silva, ADOL) containing MDV gB
and chicken GAPDH genes were used to construct standard curves. A
series of 10-fold dilutions of plasmid DNA in 5 ng/µl sheared salmon
sperm DNA (Sigma), from 106 to 10 copies per µl, was used to generate
standard curves. Ampliﬁcations of gB and chicken GAPDH sequences
were carried out in separate reactions using the following primers and
probes: gB forward, CGGTGGCTTTTCTAGGTTCG; gB reverse, CCAGTG-
GGTTCAACCGTGA; gB probe, FAM-CATTTTCGCGGCGGTTCTAGACGG-
TAMRA; GAPDH forward, ACAGAGGTGCTGCCCAGAA; GAPDH reverse,
ACTTTCCCCACAGCCTTAGCA; GAPDH probe, VIC-TCATCCCAGCGTCCACT-
TAMRA (gifts from Dr. Robert Silva, ADOL). Real-time qPCR assays were
performed using an ABI 7900 HT machine (Applied Biosystems). Each
reaction contained 0.5 µM of each primer and 0.2 µM of the
corresponding probe, 7.5 µl TaqMan® Universal PCR Master Mix
(Applied Biosystems) and 3 µl DNA template in a total reaction volume
of 15 µl. The cycling parameters consisted of 50 °C for 2min and 95 °C for
10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Viral
loads were expressed as the copy number of gB divided by that of
GAPDH. Reactions were done in duplicate. The correlation coefﬁcients
(R2 values) of the standard curves were 0.999 (GAPDH) and 0.997 (gB).
PCR ampliﬁcation efﬁciency was N0.96.
Statistical analysis
The reduction in HVT and MDV titer due to RNAi constructs was
analyzed with a simple general linear model in which the RNAi
treatment was treated as a ﬁxed variable. The statistical analysis was
accomplished with the SAS for Windows v9.1.3 (SAS Institute Inc.,
2004). The differences in average viral titers among the RNAi
treatments were compared with Duncan's multiple range tests. For
convenient visual evaluation, however, the relative average virus titer
for each of the RNAi treatments was calculated by dividing each by the
average titer of the negative control, mock infection. The standard
271M. Chen et al. / Virology 377 (2008) 265–272errors for the relative average HVT or MDV titers were estimated from
the variances and covariances corresponding to the average titer ratios
between the RNAi treatments and the negative control (mock)
following an approximate procedure as described by van Kempen
and van Vliet (2000). The reduction in HVT and MDV plaque sizes by
RNAi constructs was also analyzed using SAS with a simple general
linear model in which the RNAi treatment was treated as a ﬁxed
variable. The differences in average plaque sizes among the RNAi
treatments were compared with Tukey's Studentized Range tests.
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